Search results
Results From The WOW.Com Content Network
Opko Health (NASDAQ: OPK) Q3 2024 Earnings Call ... BioReference received New York State approval for OPKO HRD testing for homologous recombination deficiency in breast, ovarian, prostate, and ...
OPKO Health (OPK) third-quarter results benefit from higher Product revenues and RAYALDEE prescription growth.
For premium support please call: 800-290-4726 more ways to reach us
OPKO Health's (OPK) third-quarter results benefit from increase in RAYALDEE prescriptions.
A look at the shareholders of OPKO Health, Inc. can tell us which group is most powerful.The group holding the most number of shares in the company, around 46% to be precise, is individual insiders.
OPKO Health's (OPK) first-quarter results benefit from increase in RAYALDEE prescriptions. Skip to main content. 24/7 Help. For premium support please call: 800-290-4726 more ways ...
OPKO Health is a diversified healthcare company present in more than 30 countries. The company's primary businesses include [citation needed] Bioreference Laboratories, a clinical laboratory with a core genetic testing business; The 4K Test Score, a blood test for prostate cancer; Pharmaceutical development, with products such as Rayaldee
OPKO Health (OPK) gets FDA nod for its 4Kscore Test that will further validate its value of being an important tool in the diagnosis of prostate cancer.